secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001193805-25-000275
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q4 net loss widens to $30M; KOSTAIVE EC approved, Phase 2 data due Q2 2025
--------------------------------------------------------------------------------

- Q4 2024 net loss $30.0M ($1.11/share) vs $11.7M ($0.44) in Q4 2023; revenue down $8.1M to $22.8M.
- Full year 2024 revenue $152.3M (down $14.5M YoY); net loss $80.9M ($3.00/share) vs $29.7M ($1.12).
- Cash $293.9M at Dec 31, 2024; runway expected to Q1 2027; CSL reported $28M Arcturus share of KOSTAIVE gross profit.
- KOSTAIVE received European Commission approval Feb 2025; US BLA filing anticipated 2025; H5N1 vaccine Phase 1 dosed.
- ARCT-032 CF and ARCT-810 OTCD Phase 2 interim data on track for Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525000275/0001193805-25-000275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525000275/e664243_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-000275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer